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ABSTRACT
Aims/Introduction: Recent observational studies suggest elevated levels of bilirubin,
an endogenous anti-oxidant, might protect against kidney disease. We carried out an
observational cohort study to assess whether higher baseline levels of bilirubin, within nor-
mal range, could predict the rate of development and progression of diabetic nephropa-
thy in patients with type 2 diabetes.
Materials and Methods: Japanese type 2 diabetic patients with normo- or microalbu-
minuria and normal serum bilirubin (<1.2 mg/dL) were recruited from a single center, and
categorized according to baseline serum bilirubin levels. Two independent end-points
were specified: development or progression of diabetic nephropathy, based on transition
to a more advanced stage of albuminuria (albuminuria cohort), and the rate of change in
estimated glomerular filtration rate (eGFR cohort).
Results: Albuminuria and eGFR cohorts were constructed consisting of 1,915 patients and
1,898 patients, respectively, with 1,738 patients overlapping. Mean follow up was 4.4 and
5.4 years for the two cohorts, respectively. Within the albuminuria cohort, 132 (9%) of 1,418
patients with normoalbuminuria developed microalbuminuria, and 56 (11%) of 497 patients
with microalbuminuria developed macroalbuminuria. Higher baseline bilirubin levels were
associated with significantly lower risk of progression from microalbuminuria to macroalbu-
minuria in both the univariate and multivariate analyses. In normoalbuminuric patients, an
inverse association was found when restricted to a subgroup with elevated hemoglobin A1c
levels. There was no relationship between bilirubin levels and the rate of change in eGFR.
Conclusions: Higher serum bilirubin levels, within normal range, might be predictive of a
lower risk of progression of nephropathy in type 2 diabetic patients.
INTRODUCTION
Diabetic kidney disease (DKD) is the most common cause of
chronic kidney disease and end-stage kidney disease1; therefore,
an improved understanding of the factors involved in the devel-
opment and progression of DKD is urgently required. Oxida-
tive stress is a potential factor in the pathogenesis of diabetic
vascular complications including DKD2,3. In non-clinical stud-
ies, reactive oxygen species (ROS) are cytotoxic to kidney cells,
and promote inflammatory and fibrogenic reactions in the kid-
neys of diabetic rats4. Clinical studies also show a significant
association between oxidative stress and DKD5,6. Although
hyperglycemia is thought to be a contributor to oxidative stress,
uncertainty remains regarding the potential role of anti-oxidants
in slowing the progression of DKD7,8.
Bilirubin, an endogenous product of heme catabolism, is a
potent anti-oxidant that effectively scavenges peroxyl radicals,
and suppresses the oxidation of lipids and lipoproteins9. Several
non-clinical studies have shown a protective effect of bilirubin in
preventing kidney damage10,11. In diabetic patients with GilbertReceived 17 October 2012; revised 20 April 2013; accepted 21 July 2013
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syndrome, a common hereditary disorder (incidence of 5–10%
of the population) characterized by high levels of unconjugated
bilirubin, vascular complications including DKD were reported
to be infrequent12. Furthermore, serum bilirubin concentrations
were shown to be negatively correlated with urinary albumin lev-
els, and positively correlated with glomerular filtration rate
(GFR) in cross-sectional studies in patients with type 2 diabetes
mellitus12–15. In contrast, there were no associations between
serum bilirubin levels with estimated GFR (eGFR) or albumin-
uria in the USA diabetic population16. We, therefore, carried out
the present longitudinal study to further clarify the association
between serum bilirubin levels, and the development and pro-
gression of DKD in patients with type 2 diabetes.
MATERIALS AND METHODS
Participants
This was a single-center longitudinal observational cohort study
involving adult Japanese patients with type 2 diabetes. Partici-
pants were recruited from ambulatory and hospitalized patients
presenting at the Diabetes Center, Tokyo Women’s Medical
University Hospital in Tokyo, Japan, during the period from
July 2003 to December 2004. Type 2 diabetes was diagnosed
according to the Japan Diabetes Society (JDS) criteria17.
At a regular ambulatory visit or at the time of hospitaliza-
tion, participants underwent baseline anthropometric and phys-
ical examinations. Laboratory measurements included serum
bilirubin, lipids, creatinine and hemoglobin A1c (A1c) in ran-
dom spot blood samples, and urinary albumin excretion mea-
sured in the first morning urine specimen. In the present
study, patients confirmed to have normoalbuminuria or micro-
albuminuria and an eGFR ≥15 mL/min/1.73 m2 were enrolled.
Definition of normo-/microalbuminuria and estimation of GFR
are described later. Patients were excluded if their serum biliru-
bin levels were >1.2 mg/dL because of the potential for con-
founding hepatobiliary or hemolytic diseases. Patients were also
excluded if they had gallstones, cirrhosis, hepatitis B or C, alco-
holic liver disease or malignant diseases, if they had undergone
renal replacement therapy, or if they were pregnant.
The study protocol was designed and carried out in adher-
ence with the Declaration of Helsinki, and was approved by
the Ethics Committee of Tokyo Women’s Medical University
School of Medicine.
Outcome Measurements
In the present study, two independent renal outcomes were speci-
fied (Figure 1). The first was onset or progression of albuminuria,
defined as the transition from normo- to micro- or macroalbu-
minuria (onset of albuminuria), or from micro- to macroalbu-
minuria (progression of albuminuria). Both transitions required
confirmation from at least two consecutive urinary albumin-to-
creatinine ratio (ACR) measurements. Patients were followed for
at least 6 months.
The second outcome measurement was the annual rate of
decline in eGFR, as described in detail previously18. For the
analysis of this outcome, patients were excluded if their follow-
up period was <2 years from study entry (Figure 1). This
minimum observation period was selected based on a previous
recommendation for an observation period of at least 2 years
to assure valid determination of the rate of decline in eGFR19.
Patients were excluded from the analysis if the rate of change
in eGFR was equal to or >5 mL/min/1.73 m2/year (Figure 1),
as such values are clinically implausible, likely because of
imprecision in the eGFR calculation, and could artificially skew
the analyses.
Measurements
Serum bilirubin concentrations were measured by an enzymatic
method involving bilirubin oxidase using an automatic analyzer
(Hitachi Labospect 008; Hitachi, Japan; normal range
0.2–1.2 mg/dL). Serum creatinine and total cholesterol were
Adult type 2 diabetic patients with normo- or 
microalbuminuria recruited from July 2003 to
 December 2004 (n = 2,600)
Diseases of hepatobiliary systems (n = 73)
Follow-up < 2 years (n = 437)No Follow-up data on
urinary albumin (n = 452)
ACR cohort
(n = 1,915)
eGFR cohort
(n = 1,898)
Follow-up < 6 month (n = 43)
Annual rate of change in eGFR
> 5 mL/min/1.73m2/year  (n = 75)
Malignant diseases (n = 15)
Post-rental transplantation (n = 3)
Pregnacy (n = 1)
Figure 1 | The composition of the study population.
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determined by enzymatic methods. A1c was measured by high-
performance liquid chromatography (HPLC), using a set of
calibrators assigned by the JDS (normal range 4.3–5.8%). To
internationally standardize A1c values to the National Glycohe-
moglobin Standardized Program (NGSP) units, the following
formula was used: A1c (NGSP) (%) = 1.02 9 measured A1c
(JDS) (%) + 0.2520.
Urinary albumin levels were measured using the latex aggluti-
nation method, and normalized by urinary creatinine determined
by an enzymatic method. The stage of albuminuria was defined
as normoalbuminuria if urinary ACR was <30 mg/g, microalbu-
minuria if ACR was 30–299 mg/g and macroalbuminuria if
ACR was equal to or higher than 300 mg/g. GFR was esti-
mated using the following three-variable equation, as proposed
by the Japanese Society of Nephrology: eGFR (mL/min per
1.73 m2) = 194 9 age (years)-0.287 9 serum creatinine (mg/
dL)-1.094 9 0.739 (if female)21.
Statistical Analysis
Separate tertiles were obtained for normoalbuminuric and
microalbuminuric patients according to baseline bilirubin levels.
Continuous variables were expressed as arithmetic mean – SD
or geometric mean with 95% confidence interval (CI), as
appropriate according to the data distribution. Categorical data
were expressed by actual frequencies and percentages. For sta-
tistical analyses, Student’s t-test, analysis of variance (ANOVA),
Spearman’s correlational analysis, multiple regression analysis
and analysis of covariance (ANCOVA) were carried out.
Cumulative incidence of transition of albuminuria stage
was estimated by the Kaplan–Meier method, and the sta-
tistical differences among groups were examined by the
log–rank test. Hazard ratios and the corresponding 95%
CIs for reaching each outcome were calculated using uni-
variate and multivariate Cox proportional hazard model
analyses. In the multivariate Cox model, all of the follow-
ing parameters were considered as potential covariates:
age, sex, use of renin–angiotensin–aldosterone system
blockers, systolic blood pressure, diastolic blood pressure, body
mass index, A1c, high-density lipoprotein cholesterol, non-
high-density lipoprotein cholesterol, eGFR, logarithmically
transformed urinary ACR values, hemoglobin, aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT) at
baseline. Then, variables were selected using the stepwise vari-
able-selecting procedure specifying the significant levels for
entering another explanatory variable into the model as 0.25,
and that for removing an explanatory variable from the model
as 0.15, respectively. P-values <0.05 were considered signifi-
cant. All statistical analyses were carried out using the SAS
version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Baseline Demographic and Clinical Characteristics
During the entry period between July 2003 and December
2004, 2,600 adult Japanese patients with type 2 diabetes were
assessed for eligibility. A total of 1,915 patients had sufficient
baseline and follow-up data to qualify for inclusion in albumin-
uria cohort, and 1,898 patients qualified for inclusion in the
eGFR cohort, with 1,738 patients overlapping (Figure 1).
Table 1 shows the clinical and laboratory data for patients in
the albuminuria and eGFR cohorts, with the albuminuria
cohort divided into subgroups of patients with baseline normo-
albuminuria or microalbuminuria. As 1,738 patients (90.8% of
albuminuria cohort and 91.6% of GFR cohort) overlapped,
demographic and clinical characteristics of the two cohorts were
almost identical. Within the albuminuria cohort, patients with
microalbuminuria were more likely than those with normoalbu-
minuria to be men, to be older and to have higher body mass
index, systolic blood pressure, and levels of A1c and creatinine,
and lower levels of eGFR. Serum levels of total bilirubin in the
normoalbuminuria or microalbuminuria subgroups were identi-
cal. Clinical and laboratory data for patients with normoalbu-
minuria and microalbuminuria, classified according to serum
bilirubin levels, are listed in the Table 2.
Associations Between Bilirubin Levels and the Progression of
Albuminuria
In the 1,418 normoalbuminuric patients from the albuminuria
cohort, 132 patients (9.3%) progressed to microalbuminuria
during a mean follow-up period of 4.5 – 1.7 years (range 0.5–
6.9 years). As shown in Figure 2a, there were no significant dif-
ferences in the cumulative incidence of microalbuminuria
among the tertiles of baseline serum bilirubin levels (log–rank
test, P = 0.37). In the multivariate Cox regression hazard analy-
sis, hazard ratios for patients in the second and third bilirubin
tertiles were not statistically significant compared with those in
the first tertile (Table 3). Even when bilirubin level was mod-
eled as a continuous variable, there was no significant associa-
tion between serum bilirubin levels and the progression from
normoalbuminuria to microalbuminuria using either univariate
or multivariate analyses (Table 3).
Among the 497 microalbuminuric patients, 56 patients
(11.3%) progressed to macroalbuminuria during the mean fol-
low-up period of 4.3 – 2.0 years (range 0.5–7.1 years). The
cumulative incidence of macroalbuminuria significantly
decreased across increasing levels of serum bilirubin (log–rank
test, P < 0.001; Figure 2a). The adjusted hazard ratio for patients
in the third versus first tertile of bilirubin was 0.24 (95% CI
0.08–0.71, P = 0.009; Table 3). When bilirubin level was treated
as a continuous variable, higher bilirubin levels were associated
with a significantly lower risk of progression of albuminuria in
both the univariate and multivariate analyses (Table 3).
As hyperglycemia is a major contributor to oxidative stress in
diabetic patients, glycemic control per se might modify the rela-
tionship between bilirubin levels and progression of albuminuria.
Therefore, we carried out the following subanalyses, by further
dividing normo- and microalbuminuric patients into subgroups
based on the median level of A1c. In normoalbuminuric patients,
the interaction between bilirubin and A1c levels (low or high) on
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the progression of albuminuria was significant (P = 0.04). For
patients with A1c ≥7.7% (n = 668), higher bilirubin levels, trea-
ted as either categorical or continuous variables, were signifi-
cantly associated with a lower risk of progression of albuminuria
in the multivariate analysis (Table 3). For patients with A1C
<7.7% (n = 735), there was no association between bilirubin lev-
els and the progression of albuminuria. As there was no signifi-
cant interaction between bilirubin and A1C levels in
microalbuminuric patients (P = 0.69), a subanalysis based on
A1c levels was not carried out.
Associations Between Bilirubin Levels and Decline in eGFR
For the eGFR cohort, mean follow up was 5.4 – 1.1 years
(range 2.0–7.1 years), and the mean number of follow-up serum
creatinine measurements, used in determining the rate of
change in eGFR, was 13 – 9 per patient. The overall mean rate
of change in eGFR was -0.97 – 2.07 mL/min/1.73 m2/year.
Neither crude nor adjusted rate of decline in eGFR was signifi-
cantly different among patients classified according to baseline
serum bilirubin levels (Figure 3). There was also no significant
relationship between baseline bilirubin levels and the rate of
change in eGFR using simple correlational analysis (Spearman’s
correlation coefficient = 0.029, P = 0.21) or in a multivariate
regression analysis adjusted for other clinical factors (P = 0.95).
DISCUSSION
In the present single-center longitudinal observational cohort
study of patients with type 2 diabetes, we found that higher
serum bilirubin levels, within the normal range, were associated
with a lower risk of the progression from microalbuminuria to
macroalbuminuria. An association between bilirubin and pro-
gression of albuminuria was not observed in the subgroup of
patients with normoalbuminuria; however, when a subanalysis
was carried out, a lower risk of progression was observed for
patients with elevated A1c levels. These relationships were con-
firmed by treating bilirubin levels as either a continuous or cat-
egorical variable. Furthermore, these associations were
independent of other variables that are well-known risk factors
for development of DKD. In contrast, we did not find a rela-
tionship between baseline bilirubin level and the rate of GFR
decline. Previous cross-sectional studies in diabetic patients
yielded conflicting results regarding the association between
serum bilirubin levels and prevalence of albuminuria13,16,22. In
addition, cross-sectional studies do not provide definite infor-
mation about causal relationships. This is the first longitudinal
study to assess the relationship between serum bilirubin levels
and progression of albuminuria in diabetic patients, and thus
provides support for the hypothesis of a cause-and-effect rela-
tionship.
Table 1 | Demographic and laboratory data at baseline in albumin-to-creatinine ratio cohort and estimated glomerular filtration rate cohort
ACR cohort eGFR cohort
(n = 1,898)
Normoalbuminuria (n = 1,418) Microalbuminuria (n = 497) Overall (n = 1,915)
Men (%) 58.2 60.2 58.5 59.6
Age (years) 59 – 12 61 – 12 59 – 12 60 – 12
BMI (kg/m2) 23.7 – 3.4 25.0 – 4.2 24.0 – 3.7 24.0 – 3.7
Duration of diabetes (years) 14 – 9 15 – 9 14 – 9 15 – 9
Diabetic retinopathy (%) 31.7 34.3 40.4 40.9
Medication for diabetes
(none/oral/insulin)
13.0/51.2/35.8 8.2/44.4/47.4 12.2/49.3/38.5 9.8/49.3/39.9
SBP (mmHg) 132 – 19 139 – 21 134 – 19 134 – 19
DBP (mmHg) 76 – 11 76 – 12 76 – 12 76 – 12
Use of RAS blockers (%) 34.7 63.9 42.1 43.0
Use of other antihypertensive
drugs (%)
42.7 72.0 50.2 52.3
Laboratory data
A1c (%) 8.0 – 1.7 8.3 – 1.8 8.1 – 1.5 8.2 – 1.5
HDL cholesterol (mg/dL) 55 – 15 51 – 15 54 – 15 54 – 15
Non-HDL cholesterol (mg/dL) 142 – 33 134 – 50 140 – 39 138 – 40
Creatinine (mg/dL) 0.75 – 0.19 0.80 – 0.20 0.76 – 0.20 0.77 – 0.21
Total bilirubin (mg/dL) 0.5 – 0.2 0.5 – 0.2 0.5 – 0.2 0.5 – 0.2
AST (U/L) 23 – 11 24 – 13 23 – 12 23 – 12
ALT (U/L) 26 – 19 28 – 20 26 – 19 27 – 19
c-GTP (U/L) 30 (29–32) 33 (31–36) 31 (30–32) 31 (30–32)
eGFR (mL/min/1.73 m2) 77.6 – 17.7 74.2 – 20.4 76.8 – 18.5 75.9 – 18.5
Urinary ACR (mg/g) 10.0 (9.7–10.3) 74.0 (70.0–78.2) 16.6 (15.9–17.3)
c-GTP, c-glutamyl transferase; A1c, hemoglobin 1c; ACR, albumin-to-creatinine ratio; ALT, alanine transaminase; AST, aspartate transaminase; BMI,
body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; RAS, renin–angiotensin system.
ª 2013 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 5 No. 2 March 2014 231
O R I G I N A L A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi Bilirubin and diabetic kidney disease
Ta
bl
e
2
|D
em
og
ra
ph
ic
an
d
la
bo
ra
to
ry
da
ta
at
ba
se
lin
e
in
al
bu
m
in
-to
-c
re
at
in
in
e
ra
tio
co
ho
rt
an
d
es
tim
at
ed
gl
om
er
ul
ar
fil
tra
tio
n
ra
te
co
ho
rt
cl
as
sif
ie
d
by
ba
se
lin
e
bi
lir
ub
in
le
ve
ls
N
or
m
oa
lb
um
in
ur
ia
P-
va
lu
e
M
ic
ro
al
bu
m
in
ur
ia
P-
va
lu
e
Fi
rs
t
te
rti
le
(n
=
38
1)
Se
co
nd
te
rti
le
(n
=
55
3)
Th
ird
te
rti
le
(n
=
48
4)
Fi
rs
t
te
rti
le
(n
=
14
7)
Se
co
nd
te
rti
le
(n
=
20
7)
Th
ird
te
rti
le
(n
=
14
3)
Ra
ng
e
of
to
ta
lb
ilir
ub
in
(m
g/
dL
)
0.
1–
0.
4
0.
5–
0.
6
0.
7–
1.
1
0.
1–
0.
4
0.
5–
0.
6
0.
7–
1.
1
M
en
(%
)
61
.4
52
.1
62
.8
<0
.0
01
66
.0
58
.5
57
.3
0.
25
Ag
e
(y
ea
rs
)
58
–
13
60
–
12
58
–
12
0.
04
61
–
11
63
–
13
57
–
13
<0
.0
01
BM
I(
kg
/m
2 )
23
.5
–
3.
3
23
.8
–
3.
6
23
.8
–
3.
5
0.
37
24
.0
–
3.
6
25
.1
–
4.
0
26
.0
–
4.
6
<0
.0
01
D
ur
at
io
n
of
di
ab
et
es
(y
ea
rs
)
14
–
9
14
–
9
14
–
9
0.
34
16
–
10
16
–
9
12
–
8
<0
.0
01
D
ia
be
tic
re
tin
op
at
hy
(%
)
35
.2
30
.6
30
.0
0.
14
66
.7
66
.2
63
.6
0.
84
M
ed
ic
at
io
n
fo
r
di
ab
et
es
(n
on
e/
or
al
/in
su
lin
)
13
.6
/4
6.
5/
39
.9
12
.3
/5
2.
8/
34
.9
10
.5
/5
3.
3/
32
.6
0.
10
6.
8/
39
.5
/5
3.
7
11
.6
/3
8.
2/
50
.2
7.
7/
57
.3
/3
5.
0
0.
00
2
SB
P
(m
m
H
g)
13
1
–
18
13
3
–
19
13
1
–
19
0.
24
13
8
–
22
13
9
–
22
14
1
–
19
1
0.
50
D
BP
(m
m
H
g)
74
–
11
76
–
12
77
–
11
0.
00
5
75
–
12
76
–
12
78
–
12
0.
03
U
se
of
RA
S
bl
oc
ke
rs
(%
)
33
.3
35
.3
34
.9
0.
83
65
.3
64
.7
60
.8
0.
68
U
se
of
ot
he
r
an
tih
yp
er
te
ns
iv
e
dr
ug
s
(%
)
42
.3
43
.8
41
.9
0.
82
73
.5
72
.5
69
.9
0.
76
La
bo
ra
to
ry
da
ta
A1
c
(%
)
8.
0
–
1.
5
8.
0
–
1.
5
8.
1
–
1.
5
0.
42
8.
4
–
1.
6
8.
5
–
1.
6
8.
4
–
1.
6
0.
88
H
D
L
ch
ol
es
te
ro
l(
m
g/
dL
)
54
–
15
55
–
15
56
–
16
0.
48
52
–
16
52
–
15
50
–
13
0.
29
N
on
-H
D
L
ch
ol
es
te
ro
l(
m
g/
dL
)
14
2
–
37
14
3
–
32
14
1
–
33
0.
83
13
5
–
48
13
1
–
54
13
5
–
47
0.
71
Cr
ea
tin
in
e
(m
g/
dL
)
0.
75
–
0.
19
0.
74
–
0.
20
0.
76
–
0.
20
0.
17
0.
85
–
0.
26
0.
80
–
0.
22
0.
73
–
0.
18
<0
.0
01
To
ta
lb
ilir
ub
in
(m
g/
dL
)
0.
3
–
0.
1
0.
5
–
0.
1
0.
8
–
0.
1
<0
.0
01
0.
3
–
0.
1
0.
5
–
0.
1
0.
8
–
0.
1
<0
.0
01
AS
T
(U
/L
)
22
–
10
23
–
9
24
–
13
0.
03
23
–
10
25
–
12
25
–
12
0.
16
AL
T
(U
/L
)
25
–
16
25
–
15
29
–
24
0.
00
2
25
–
16
28
–
23
31
–
20
0.
06
c-
G
TP
(U
/L
)
30
(2
8–
33
)
30
(2
9–
32
)
30
(2
9–
32
)
0.
19
34
(3
0–
38
)
33
(3
0–
37
)
33
(3
0–
38
)
0.
75
eG
FR
(m
L/
m
in
/1
.7
3
m
2 )
79
.0
–
19
.6
76
.9
–
16
.5
77
.5
–
17
.6
0.
20
71
.3
–
22
.3
72
.0
–
19
.5
80
.5
–
18
.5
<0
.0
01
U
rin
ar
y
AC
R
(m
g/
g)
9.
5
(9
.1–
10
.0
)
10
.0
(9
.5–
10
.4
)
10
.2
(9
.7–
10
.6
)
0.
46
81
.3
(7
7.
7–
85
.0
)
73
.3
(7
0.
0–
76
.7
)
72
.9
(6
9.
7–
76
.3
)
0.
09
D
at
a
ar
e
ex
pr
es
se
d
as
pe
rc
en
ta
ge
,m
ea
n
–
SD
or
ge
om
et
ric
m
ea
n
(9
5%
co
nf
id
en
ce
in
te
rv
al
).
Ca
te
go
ric
al
da
ta
w
er
e
co
m
pa
re
d
us
in
g
Fi
sh
er
’s
ex
ac
t
pr
ob
ab
ilit
y
te
st
or
th
e
Co
ch
ra
n–
Ar
m
ita
ge
tre
nd
te
st
,a
nd
co
nt
in
uo
us
da
ta
w
er
e
co
m
pa
re
d
by
AN
O
VA
.c
-G
TP
,c
-g
lu
ta
m
yl
tra
ns
pe
pt
id
as
e;
A
CR
,a
lb
um
in
-to
-c
re
at
in
in
e
ra
tio
;A
LT
,a
la
ni
ne
am
in
ot
ra
ns
fe
ra
se
;A
ST
,a
sp
ar
at
at
e
am
in
ot
ra
ns
fe
ra
se
;B
M
I,
bo
dy
m
as
s
in
de
x;
D
BP
,d
ia
st
ol
ic
bl
oo
d
pr
es
su
re
;e
G
FR
,e
st
im
at
ed
gl
om
er
ul
ar
fil
tra
tio
n
ra
te
;H
D
L,
hi
gh
-d
en
sit
y
lip
op
ro
te
in
;O
H
A
,o
ra
lh
yp
og
ly
ce
m
ic
ag
en
ts
;
RA
S,
re
ni
n–
an
gi
ot
en
sin
sy
st
em
;S
BP
,s
ys
to
lic
bl
oo
d
pr
es
su
re
.
232 J Diabetes Invest Vol. 5 No. 2 March 2014 ª 2013 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd
O R I G I N A L A R T I C L E
Toya et al. http://onlinelibrary.wiley.com/journal/jdi
Hyperglycemia causes mitochondrial superoxide overproduc-
tion in vascular endothelial cells. Of the many enzymatic sys-
tems implicated in ROS generation in the kidney, nicotinamide
adenine dinucleotide phosphate oxidase (NOX) is considered to
be particularly important23–25. Among the renal NOXs, NOX-4
is most abundantly expressed in the kidney23,24,26. A recent
animal study has shown that in diabetic rats with hereditary
hyperbilirubinemia, expression of NOX-4 in the kidney was
suppressed, resulting in protection against progression of DKD,
specifically by suppressing renal mesangial expansion and pre-
venting albuminuria11. Furthermore, bilirubin is known to have
anticomplement properties27, and to inhibit protein kinase C
activity28. These biological properties of bilirubin might contrib-
ute to the findings in diabetic kidney disease observed in the
present study, as well as in the apparent protective effect of bili-
rubin in cardiovascular diseases29,30.
In normoalbuminuric patients, higher serum bilirubin levels
were associated with a lower risk of progression of albuminuria
only for the subgroup of patients with poorer glycemic control.
Patients with poor glycemic control are likely to have more oxi-
dative stress, partly through increased expression of NOX-4
compared with those with good glycemic control31,32. Diabetic
patients with microalbuminuria are also more likely to have
increased oxidative stress compared with those with normoal-
buminuria33,34. Taken together, the present results suggest that
bilirubin might have a protective role in progression of diabetic
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Figure 2 | Comparison of cumulative incidence of (a) development of microalbuminuria in normoalbuminuric patients and (b) progression to
macroalbuminuria in microalbuminuric patients among three groups classified into tertiles by baseline bilirubin levels. Blue line: lowest bilirubin
tertile (T1; 0.1–0.4 mg/dL); red line: middle bilirubin tertile (T2; 0.5–0.6 mg/dL); green line: highest bilirubin tertile (T3; 0.7–1.1 mg/dL). Numbers
below the curves indicate the number of patients at risk. The difference among three groups was significant as determined by the log–rank test in
(b) microalbuminuric patients (P < 0.001), but not in (a) normoalbuminuric patients (P = 0.37).
Table 3 | Univariate and multivariate hazard ratio of progression of albuminuria in diabetic patients with normoalbuminuria and microalbuminuria
treating serum bilirubin levels as continuous and categorical variables
Hazard ratio (95% CI) by tertiles of serum bilirubin
levels compared with first tertile as a reference group
Hazard ratio (95% CI)
for an increment
of 0.1 mg/dL serum
bilirubinSecond tertile Third tertile
Normoalbuminuria
Univariate analysis 0.73 (0.48–1.13) 0.87 (0.57–1.33) 0.98 (0.91–1.07)
Multivariate analysis
Overall (n = 1,403) 0.70 (0.44–1.12) 0.77 (0.49–1.22) 0.94 (0.85–1.03)
A1c <7.7% (n = 668) 0.95 (0.39–2.29) 1.49 (0.64–3.47) 1.11 (0.95–1.28)
A1c ≥7.7% (n = 735) 0.53 (0.31–0.91)* 0.51 (0.29–0.88)* 0.87 (0.70–0.99)*
Microalbuminuria
Univariate analysis 0.56 (0.32–0.98)* 0.21 (0.09–0.50)* 0.73 (0.62–0.86)*
Multivariate analysis 0.63 (0.34–1.17) 0.24 (0.08–0.71)* 0.77 (0.64–0.92)*
*P < 0.05. A1c, hemoglobin 1c, CI, confidence interval.
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nephropathy, particularly in diabetic patients with greater oxi-
dative stress. Further studies will be required to address the
potential mechanisms by which bilirubin might protect against
progression of diabetic kidney disease.
In contrast to the progression of albuminuria, changes in
eGFR were not associated with bilirubin levels, which was
inconsistent with previous cross-sectional studies13–15.
Although the reasons for this are not clear, several explana-
tions might be postulated. Participants in this diabetic cohort
had no or only mild nephropathy (normo-or microalbuminu-
ria), whereas in the typical natural history of DKD, GFR has
been considered to decline subsequent to development of
macroalbuminuria35–37. Therefore, the follow-up period in the
present study might be inadequate to evaluate GFR decline.
The UK Prospective Diabetes Study found different risk fac-
tors for the progression of albuminuria and decline in GFR38.
Therefore, the present results might reflect differences of the
pathogenesis of the two renal manifestations, albuminuria and
decline in GFR, in diabetes.
The present study had several limitations. First, we were
unable to completely exclude patients with hepatobiliary or
hemolytic disease. Second, we did not differentiate direct and
indirect bilirubin from total serum bilirubin. Third, we did not
evaluate the effect of time-dependent changes in serum biliru-
bin levels. Fourth, we did not investigate alcohol use, smoking
and socioeconomic status or physical exercise. Fifth, informa-
tion on the use of antihypertensive drugs, including renin–
angiotensin–aldosterone system blockers, was obtained only at
baseline and not during the follow-up period. Finally, the pres-
ent study was carried out in an urban university hospital in an
ethnically homogenous population in Japan, which might not
be representative of other type 2 diabetic patient populations.
Conversely, the large sample size, prospective study design and
consistent use of first-morning specimens for measurement of
albuminuria are strengths of the study.
In conclusion, the present observational cohort study provided
evidence that higher serum bilirubin levels are associated with
lower risk of the progression of albuminuria in patients with mi-
croalbuminuria and in normoalbuminuric patients with poor gly-
cemic control. In light of the present findings, serum bilirubin
levels, easily measured in conjunction with traditional risk fac-
tors, could help identify diabetic patients at higher or lower risk
of DKD progression. These findings require confirmation in pro-
spective, multicenter studies, as well as in non-diabetic kidney
diseases. The relationship between serum bilirubin levels and dia-
betic macrovascular diseases, in which oxidative stress has also
been implicated, should be assessed in future studies.
ACKNOWLEDGEMENTS
No potential conflicts of interest relevant to this article were
reported.
REFERENCES
1. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in
type 2 diabetes: a medical catastrophe of worldwide
dimensions. Am J Kidney Dis 1999; 34: 795–808.
2. Giacco F, Brownlee M. Oxidative stress and diabetic
complications. Circ Res 2010; 107: 1058–1070.
3. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a
major culprit in kidney disease in diabetes. Diabetes 2008;
57: 1446–1454.
4. Wang K, Zhou Z, Zhang M, et al. Peroxisome receptor for
advanced glycation end products and inhibits smooth muscle
cell proliferation in a diabetic and nondiabetic rat carotid
artery injury model. J Pharmacol Exp Ther 2006; 31: 37–43.
5. Rashidi A, Nakhjavani M, Esteqhamati A, et al. Association
between oxidant/antioxidant markers and proteinuria in
type 2 diabetes: results in 142 patients. J Nephrol 2009; 22:
733–738.
6. Niwa T, Katsuragi T, Miyazaki S, et al. Immunohistochemical
detection of imidazolone, a novel advanced glycation end
product in kidneys and aortas of diabetic patients. J Clin
Invest 1997; 99: 1272–1280.
7. Yamagishi S, Matsui T. Advanced glycation endproducts,
oxidative stress and diabetic nephropathy. Oxid Med and
Cell Longev 2010; 3: 101–108.
8. Ceriello A. New insights on oxidative stress and diabetic
complications may lead to a “causal” antioxidant therapy.
Diabetes Care 2003; 26: 1589–1596.
9. Stocker R, Yamamoto Y, McDoagh AF, et al. Bilirubin is an
antioxidant of possible physiological importance. Science
1987; 235: 1043–1046.
10. Adin CA, Croker BP, Agarwal A. Protective effect of
exogenous bilirubin on ischemia-reperfusion injury in the
isolated, perfused rat kidney. Am J Physiol Renal Physiol
2005; 288: F778–F784.
0.0
(a) (b)
T1 T2
Crude
Ra
te
 o
f c
ha
ng
e 
in
 e
G
FR
 a
cc
or
di
ng
 to
ba
se
lin
 s
er
um
 b
ili
ru
bi
n 
le
ve
ls
(m
L/
m
in
/1
.7
3 
m
2 )
Adjusted
T3 T1 T2 T3
–0.2
–0.4
–0.6
–0.8
–1.0
–1.2
Figure 3 | Comparison of rate of change in estimated glomerular
filtration rate (eGFR) among groups classified according to baseline
serum bilirubin levels: lowest bilirubin tertile (T1; n = 526), middle
bilirubin tertile (T2; n = 745) and highest bilirubin tertile (T3; n = 627),
in (a) the crude model using ANOVA and in (b) the adjusted model
(ANCOVA). There was no significant difference in the rate in the either
crude or adjusted model.
234 J Diabetes Invest Vol. 5 No. 2 March 2014 ª 2013 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd
O R I G I N A L A R T I C L E
Toya et al. http://onlinelibrary.wiley.com/journal/jdi
11. Fujii M, Inoguchi T, Sasaki S, et al. Bilirubin and biliverdin
protect rodents against diabetic nephropathy by downre-
gulating NAD(P)H oxidase. Kidney Int 2010; 78: 905–919.
12. Inoguchi T, Sasaki S, Kobayashi K, et al. Relationship
between Gilbert syndrome and prevalence of vascular
complications in patients with diabetes. JAMA 2007; 298:
1398–1400.
13. Fukui M, Tanaka M, Shiraishi E, et al. Relationship between
serum bilirubin and albuminuria in patients with type 2
diabetes. Kidney Int 2008; 74: 1197–1201.
14. Han SS, Na KY, Chae DW, et al.High serum bilirubin is associ-
ated with the reduced risk of diabetesmellitus and diabetic
nephropathy. Tohoku J ExpMed 2010; 221: 133–140.
15. Zelle DM, Deetman N, Alkhalf A, et al. Support for a
protective effect of bilirubin on diabetic nephropathy in
humans. Kidney Int 2011; 79: 686–687.
16. Targher G, Bosworth C, Kendrick J, et al. Relationship of
serum bilirubin concentrations to kindey function and
albuminuria in the United States adult population. Findings
from the national health and nutrition examination survey
2001-2006. Clin Chem Lab Med 2009; 47: 1055–1062.
17. Kuzuya T, Nakagawa S, Satoh J, et al. The committee of the
Japan diabetes society on the diagnostic criteria of diabetes
mellitus, report of the committee on the classification and
diagnostic criteria of diabetes mellitus. Diabetes Res Clin
Pract 2002; 55: 65–85.
18. Babazono T, Hanai K, Suzuki K, et al. Higher levels of urinary
albumin excretion within the normal range predict faster
decline in glomerular filtration rate in diabetic patients.
Diabetologia 2006; 49: 1387–1393.
19. Levey AS, Gassman JJ, Hall PM, et al. Assessing the
progression of renal disease in clinical studies: effects of
duration of follow-up and regression to the mean.
Modification of diet in renal disease (MDRD) study group.
J Am Soc Nephrol 1991; 1: 1087–1094.
20. Kashiwagi A, Kasuga M, Araki E, et al. Committee on the
standardization of diabetes mellitus-related laboratory testing
of Japan diabetes society (JDS): International clinical
harmonization of glycated hemoglobin in Japan: from Japan
diabetes society to national glycohemoglobin standardization
program values. J Diabetes Invest 2012; 3: 39–40.
21. Matsuo S, Imai E, Horio M, et al. Revised equations for
estimated GFR from serum creatinine in Japan. Am J Kidney
Dis 2009; 53: 982–992.
22. Shin HS, Jung YS, Rim H. Relationship of serum bilirubin
concentration to kidney function and 24-hour urine protein
in Korean adults. BMC Nephrol 2011; 12: 29.
23. Gill PS, Willcox CS. NADPH oxidase in kidney. Antioxid Redox
Signal 2006; 8: 1597–1607.
24. Orient A, Donko A, Szabo A, et al. Novel sources of reactive
oxygen species in human body. Nephrol Dial Transplant
2007; 22: 1281–1288.
25. Satoh M, Fujimoto S, Haruna Y, et al. NAD(P)H oxidase and
uncoupled nitric oxide synthase are major sources of
glomerular superoxide in rats with experimental diabetic
nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144–
F1152.
26. Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases:
not just in mammals. Biochimie 2007; 89: 1107–1112.
27. Nakagami T, Toyomura K, Kinoshita T, et al. A beneficial role
of bile pigments as an endogenous tissue protector: anti-
complement effects of biliverdin and conjugated bilirubin.
Biochim Biophys Acta 1993; 1158: 189–193.
28. Sano K, Nakamura H, Matsuo T. Mode of inhibitory action
of bilirubin on protein kinase C. Pediatr Res 1985; 19: 587–
590.
29. Schwertner HA, Jackson WG, Tolan G. Association of low
serum concentration of bilirubin with increased risk of
coronary artery disease. Clin Chem 1994; 40: 18–23.
30. Djousse L, Levy D, Cupples LA, et al. Total serum bilirubin
and risk of cardiovascular disease in the Framingham
offspring study. Am J Cardiol 2001; 87: 1196–1200.
31. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-
based NADPH oxidase in glucose-induced oxidative stress in
the kidney: implications in type 2 diabetic nephropathy. Am
J Physiol Renal Physiol 2010; 299: F1348–F1358.
32. Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase
mediates hypertrophy and fibronectin expression in the
diabetic kidney. J Biol Chem 2005; 280: 39616–39626.
33. Aslan M, Sabuncu T, Kocyigit A, et al. Relationship between
total oxidant status and severity of diabetic nephropathy in
type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2007;
17: 734–740.
34. Cvetkovic T, Mitic B, Lazarevic G, et al. Oxidative stress
parameters as possible urine markers in patients with
diabetic nephropathy. J Diabetes Complications 2009; 23:
337–342.
35. Viberti GC, Jarrett RJ, Mahmud U, et al. Microalbuminuria as
a predictor of clinical nephropathy in insulin-dependent
diabetes mellitus. Lancet 1982; 1: 1430–1432.
36. Parving HH, Oxenboll B, Svendsen PA, et al. Early detection
of patients at risk of developing diabetic nephropathy: a
longitudinal study of urinary albumin excretion. Acta
Endocrinol (Copenh) 1982; 100: 550–555.
37. Mogensen CE, Christensen CK. Predicting diabetic
nephropathy in insulin- dependent patients. N Engl J Med
1984; 311: 89–93.
38. Retnakaran R, Cull CA, Thorne KI; for the UKPDS Study
Group, et al. Risk factors for renal dysfunction in type 2
diabetes U.K. prospective diabetes study 74. Diabetes 2006;
55: 1832–1839.
ª 2013 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 5 No. 2 March 2014 235
O R I G I N A L A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi Bilirubin and diabetic kidney disease
